Efforts to develop molecular biomarkers of HRD have included transcriptomic signatures [66], mutational signatures [67], BRCA1 and RAD51 promoter hypermethylation [68], and functional biomarkers. This evidence concerns the gene RAD51 and hypoparathyroidism-retardation-dysmorphism syndrome.